Bristol Myers Squibb Soars Amid Bullish 2026 Outlook Despite Legacy Drug Challenges | MarketWire

Bristol Myers Squibb shares climb as the firm projects strong 2026 growth, overshadowing weaker performance in its legacy drug portfolio.